Sign In
Buy OCX
$3.20
+0 (+0%)
At Close: Sep 16, 2025
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
04:15pm, Wednesday, 04'th Dec 2024
IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay.
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
07:14pm, Monday, 02'nd Dec 2024
IRVINE, Calif., Dec. 02, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft�
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
04:05pm, Monday, 02'nd Dec 2024
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft™,�
OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript
08:52pm, Tuesday, 12'th Nov 2024
OncoCyte Corporation (NASDAQ:OCX ) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025
04:06pm, Tuesday, 12'th Nov 2024
IRVINE, Calif., Nov.
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
04:45pm, Wednesday, 06'th Nov 2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12
04:42pm, Wednesday, 06'th Nov 2024
Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m.
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
04:16pm, Wednesday, 16'th Oct 2024
IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire – Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles
04:15pm, Wednesday, 16'th Oct 2024
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Ev
Insider Buying Slows, but Not for 7 These Buyers
09:45am, Sunday, 13'th Oct 2024
24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
08:31am, Tuesday, 08'th Oct 2024
IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its propriet
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
08:30am, Tuesday, 08'th Oct 2024
Results published in peer-reviewed journal , Clinical Cancer Research Study validates DetermaIO's utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targe
Oncocyte Signs Leading Transplant Centers in US and Germany
07:13pm, Wednesday, 02'nd Oct 2024
IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
07:12pm, Wednesday, 02'nd Oct 2024
Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or
Oncocyte Signs Leading Transplant Centers in US and Germany
06:41pm, Wednesday, 02'nd Oct 2024
IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers inc
